Drug Profile

AGA 2118

Alternative Names: AGA-04; AGA-2118

Latest Information Update: 06 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Angitia
Class Bispecific antibodies; Osteoporosis therapies
Mechanism of Action DKK1 protein inhibitors; SOST protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Osteoporosis

Most Recent Events

04 Nov 2024 Phase-II clinical trials in Osteoporosis (In adults, In the elderly) (SC) (NCT06577935)
30 Sep 2024 Efficacy and adverse events data from a phase I trial in Osteoporosis released by Angitia Biopharmaceuticals
27 Sep 2024 Efficacy, adverse event and pharmacokinetic data from a phase I trial in Osteoporosis presented at the Annual Meeting of the American Society for Bone and Mineral Research 2024 (ASBMR-2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com